In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrusâ„¢ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrusâ„¢ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
The addition of Olink to the Synexa Life Sciences technology portfolio demonstrates our continued commitment to strengthening our biomarker and bioanalysis capabilities across several expertise areas including oncology, immuno-oncology, infectious diseases and more.
Oncuria Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.
Liviniti, a national PBM leader in transparency and prescription drug savings, announces a new collaboration with Mindera Health to improve management of moderate-to-severe psoriasis...
The collaborative study between Sheffield Hallam University and aims to gain a better understanding of Alzheimer's Disease (AD) in order to identify those more at risk of developing the disease, so enabling the provision of appropriate interventions much earlier in the disease pathology.
Today they announced that twelve new companies have entered its Venture Lab acceleration program for early-stage companies. The cohort is strategically aligned with BII’s focus on supporting innovative early-stage start-ups that can improve human and planetary health.
Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientificâ„¢ Dionexâ„¢ Inuvionâ„¢ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."
The Callistoâ„¢ Sample Prep System offers programmable, precise, and plastic-free liquid manipulation with pre-optimized applications to support short- and long-read sequencing workflows. With a growing menu of library prep kits powered by Watchmaker Genomics' solutions, Volta Labs will continue to expand the universe of pre-optimized applications available through Callisto and enable labs to maximize advancements in sequencing.
The new HiFi library prep kits are expected to be available for purchase in the first quarter of 2024, with delivery planned early in the second quarter of 2024. Automated protocols will first be available on the Hamilton NGS STAR system, with qualified protocols on additional PacBio Compatible automation platform partners being added in the future. Kits contain enough volume for customers to develop their own automated methods notes PacBio.
“We believe that the NADMED method will advance science and medical practice by enabling larger and quicker clinical trials and in due course, diagnostics. NAD measuring should be seen as a first-line diagnostic tool in the future to fight for example degenerative diseases and metabolic disorders."
The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).
By using this website you agree to accept Medical Device News Magazine Privacy Policy